Though it has been described in several cancer types [8–13], oligoprogressive disease is best characterized in patients with epidermal growth factor receptor (EGFR) positive and anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC) treated with receptor tyrosine kinase inhibitors (TKI) [7]. Here, ALK is linked to non-small cell lung carcinoma.